Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centro De Inmunologia Molecular has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units. LU, CHENG is the named busiest examiner, with 1 pending action.
The distribution calls for coordinated but separate prosecution management. Counsel should preserve consistent biotechnology disclosures while responding to the distinct examiner and art-unit contexts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 1 | 53.8% | +64.6% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18663847 | METHOD FOR THE TREATMENT OF PATIENTS WITH CARCINOMAS | LU, CHENG | — |
| 18630519 | MONOCLONAL ANTIBODY AND A METHOD THEREOF | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18663847 | METHOD FOR THE TREATMENT OF PATIENTS WITH CARCINOMAS | LU, CHENG | 1642 | §103§112Other | Non-Final OA | — | Pending | May 14, 2024 |
| 18630519 | MONOCLONAL ANTIBODY AND A METHOD THEREOF | SKELDING, ZACHARY S | 1644 | §112DP | Non-Final OA | — | Pending | Apr 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentro De Inmunologia Molecular has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Cheng Lu has the most, with 1 of Centro De Inmunologia Molecular's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
